Related Experiment Video

Updated: Feb 5, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

CDK4 inhibitors an emerging strategy for the treatment of melanoma

Belinda Lee1,1, Grant A McArthur1,2,3,4,5,1,2,3,4,5

  • 1Department of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia.

Melanoma Management
|September 8, 2018
PubMed

Insights

Targeted therapies for melanoma are advancing beyond BRAF inhibitors. Research highlights the p16INK4A-cyclin D-CDK4/6-RB pathway

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Targeted therapies, like BRAF inhibitors, have improved advanced melanoma treatment.
  • Genomic understanding of melanoma supports expanding targeted therapies for precision medicine.
  • The p16INK4A-cyclin D-CDK4/6-retinoblastoma protein (RB) pathway is frequently dysregulated in melanoma.

Purpose of the Study:

  • To review the mechanisms, background, and progress of small molecule CDK4 inhibitors.
  • To discuss the role of CDK4 inhibitors in the management of melanoma.
  • To highlight the importance of understanding the RB pathway in melanoma development.

Main Methods:

  • Review of existing scientific literature on CDK4 inhibitors and melanoma.
  • Analysis of the interaction between the RB pathway and the RAS/RAF/MEK/ERK pathway.
  • Discussion of the genetic and biochemical processes driving melanomagenesis.

Main Results:

  • The RB pathway is dysregulated in over 90% of melanomas.
  • The RB pathway interacts with the RAS/RAF/MEK/ERK pathway, crucial for melanoma growth.
  • Small molecule CDK4 inhibitors represent a promising therapeutic strategy.

Conclusions:

  • Targeting CDK4 offers a rational approach to melanoma treatment beyond BRAF inhibition.
  • Understanding pathway interactions is essential for developing effective precision medicines.
  • CDK4 inhibitors show potential for improving outcomes in advanced melanoma management.
Keywords:
CDK inhibitorsCDK4CDKN2Acyclin Dcyclin-dependent kinasesmelanomap16

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Concept Videos

Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
786
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
613
Emerging Adulthood01:27

Emerging Adulthood

Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
700
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
373
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
544